Have a personal or library account? Click to login
Late Onset of Multiple Basal Cell Carcinomas in a Patient with Gorlin-Goltz Syndrome Previously Treated for Hodgkin’s Lymphoma/ Kasna pojava multiplog bazocelularnog karcinoma kod pacijenta sa Gorlin-Golcovim sindromom prethodno lečenog od Hočkinovog limfoma Cover

Late Onset of Multiple Basal Cell Carcinomas in a Patient with Gorlin-Goltz Syndrome Previously Treated for Hodgkin’s Lymphoma/ Kasna pojava multiplog bazocelularnog karcinoma kod pacijenta sa Gorlin-Golcovim sindromom prethodno lečenog od Hočkinovog limfoma

Serbian Journal of Dermatology and Venereology
Volume 6 (2014): Issue 1 (March 2014)
By: Rumyana Yankova,  Magdalina Gyurova and  Donka Brambarova  
Open Access
|Jul 2014

References

  1. 1. Ferreres JR, Macaya A, Jucgla A, Muniesa C, Prats C, Peyri J. Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol. 2006;20:877-8.10.1111/j.1468-3083.2006.01552.x
    Search in Google Scholar
  2. 2. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanol J Rare Dis. 2008;3:32- 48.10.1186/1750-1172-3-32
    Search in Google Scholar
  3. 3. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, Kerl H. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007;157(Suppl 2):47-51.10.1111/j.1365-2133.2007.08273.x
    Search in Google Scholar
  4. 4. Ortega Garcia de Amezaga A, Garcia Arregui O, Yepeda Nuno S, Acha Sagredo A, Aguirre Urizar JM. Gorlin-Goltz syndrome: clinicopathologic aspects. Med Oral Patol Oral Cir Bucal. 2008;13(6):E338-43.
    Search in Google Scholar
  5. 5. Dierks C. Small molecules in oncology: GDC-0449: targeting the hedgehog signaling pathway. Recent Results in Cancer Res. 2010;184:235-8.10.1007/978-3-642-01222-8_17
    Search in Google Scholar
  6. 6. Bree AF, Shah MR, BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet. 2011;155A (9):2091-7.10.1002/ajmg.a.34128
    Search in Google Scholar
  7. 7. Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69:299-308.10.1002/(SICI)1096-8628(19970331)69:3<;299::AID-AJMG16>3.0.CO;2-M
    Search in Google Scholar
  8. 8. Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30:460-4.10.1136/jmg.30.6.460
    Search in Google Scholar
  9. 9. Jones EA, Sajid MI, Shenton A, Evans DG. Basal cell carcinomas in Gorlin syndrome: a review of 202 patients. J Skin Cancer. 2011;2011:217378.10.1155/2011/217378
    Search in Google Scholar
  10. 10. Kimonis VE, Singh KE, Zhong R, Pastakia B, Digiovanna JJ, Bale SJ. Clinical and radiological features in young individuals with nevoid basal cell carcinoma syndrome. Genet Med. 2013;15:79-83.10.1038/gim.2012.96
    Search in Google Scholar
  11. 11. Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib: a syndrome. N Engl J Med. 1960;262:908-12.10.1056/NEJM196005052621803
    Search in Google Scholar
  12. 12. Jarisch W. Zur Lehre von den Hautgeschwulsten. Arch Dermatol Syphilol. 1894;28:162-222.10.1007/BF01843725
    Search in Google Scholar
  13. 13. White JC. Multiple benign cystic epitheliomas. J Cutan Genitourin Dis. 1894;12:477-84.
    Search in Google Scholar
  14. 14. Binkley GW, Johnson HH. Epithelioma adenoides cysticum: basal cell nevi, agenesis of the corpus callosum and dental cysts: a clinical and autopsy study. AMA Arch Dermatol Syphiol. 1951;63:73-84.10.1001/archderm.1951.01570010076006
    Search in Google Scholar
  15. 15. Gorlin RJ, Yunis JJ, Tuna N. Multiple nevoid basal cell carcinoma, odontogenic keratocysts and skeletal anomalies: a syndrome. Acta Derm Venereol. 1963;43:39-55.
    Search in Google Scholar
  16. 16. Gorlin RJ, Vickers RA, Kelln E, Williamson JJ. Multiple basal cell nevi syndrome. An analysis of a syndrome consisting of multiple nevoid basal-cell carcinoma, jaw cysts, skeletal anomalies, medulloblastoma, and hyporesponsiveness to parathormone. Cancer 1965;18:89-104.10.1002/1097-0142(196501)18:1<;89::AID-CNCR2820180114>3.0.CO;2-9
    Search in Google Scholar
  17. 17. Jawa DS, Sircar K, Somani R, Grover N, Jaidka S, Singh S. Gorlin-Goltz syndrome. J Oral Maxillofac Pathol. 2009;13:89-92.10.4103/0973-029X.57677
    Search in Google Scholar
  18. 18. Patil KV, Mahima G, Gupta B. Gorlin syndrome: a case report. J Indian Soc Pedod Prev Dent. 2005;23:198-203.10.4103/0970-4388.19010
    Search in Google Scholar
  19. 19. Shivaswamy KN, Sumathy TK, Shyamprasad AL, Ranganathan C. Gorlin syndrome or basal cell nevus syndrome (BCNS): a case report. Dermatol Online J. 2010;16(9):6.10.5070/D39033W6FH
    Search in Google Scholar
  20. 20. Kohli M, Kohli M, Sharma N, Siddiqui SR, Tulsi SP. Gorlin- Goltz syndrome. Natl J Maxillofac Surg. 2010;1(1):50-2.10.4103/0975-5950.69171
    Search in Google Scholar
  21. 21. Blackburn EH. Cancer interception. Cancer Prev Res (Phila). 2011;4:787-92.10.1158/1940-6207.CAPR-11-0195
    Search in Google Scholar
  22. 22. Casaroto AR, Loures DC, Moreschi E, Veltrini VC, Trento CL, Gottardo VD, et al. Early diagnosis of Gorlin-Goltz syndrome: case report. Head Face Med. 2011;7:2.10.1186/1746-160X-7-2
    Search in Google Scholar
  23. 23. Leonardi R, Santarelli A, Barbato E, Ciavarella D, Bolouri S, Harle F, et al. Atlanto-occipital ligament calcification: a novel sign in nevoid basal cell carcinoma syndrome. Anticancer Res. 2010;30(10):4265-7.
    Search in Google Scholar
  24. 24. Pinto LSS, Carlos-Bregni R, Junior HM, Filho MRM, Azanero WD, Leon JE, et al. Nevoid basal cell carcinoma syndrome: an analysis of four familial and two sporadic cases. J Oral Diag. 2012;1(1):20-5.
    Search in Google Scholar
  25. 25. Yordanova I, Gospodinov D, Kirov V, Pavlova V, Radoslavova G. A familial case of Gorlin-Goltz syndrome. J IMAB - Ann Proceed (Scient Papers). 2007;13(1):63-7.
    Search in Google Scholar
  26. 26. Potaznik D, Steinherz P. Multiple nevoid basal cell carcinoma syndrome and Hodgkin’s disease. Cancer. 1984;53(12):2713-5.10.1002/1097-0142(19840615)53:12<;2713::AID-CNCR2820531226>3.0.CO;2-Z
    Search in Google Scholar
  27. 27. Zvulunov A, Strother D, Zirbel G, Rabinowitz LG, Esterly NB. Nevoid basal cell carcinoma syndrome. Report of a case with associated Hodgkin’s disease. J Pediatr Hematol Oncol. 1995;17(1):66-70.10.1097/00043426-199502000-000127743241
    Search in Google Scholar
  28. 28. Penel N, Robin YM, Mallet Y, Gauthier H, Vanseymortier L. Association head and neck angiosarcoma and nevoid basal cell carcinoma syndrome (Gorlin syndrome). Oral Oncol Extra. 2005;41:289-91.10.1016/j.ooe.2005.07.004
    Search in Google Scholar
  29. 29. Pereira CM, Lopes AM, Meneghini AJ, Silva AF, Botelho TdeL. Oral diffuse B-cell non-Hodgkin’s lymphoma associated to Gorlin-Goltz syndrome: a case report with one year followup. Indian J Pathol Microbiol. 2011;54:388-90.10.4103/0377-4929.8164921623100
    Search in Google Scholar
  30. 30. Schulz-Butulis BA, Gilson R, Farley M, Keeling JH. Nevoid basal cell carcinoma syndrome and non-Hodgkin’s lymphoma. Cutis. 2000;66:35-8.
    Search in Google Scholar
  31. 31. Mitropoulos P, Norman R. Nevoid basal cell carcinoma syndrome (Gorlin syndrome): updated review of minimally invasive treatments. Cutis. 2008;81:53-60.
    Search in Google Scholar
  32. 32. Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol. 2007;6(9):910-4.
    Search in Google Scholar
  33. 33. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006;32(1):63-9.10.1097/00042728-200601000-00011
    Search in Google Scholar
  34. 34. Torres A, Niemeyer A, Berkes B, Marra D, Schanbacher C, Gonzalez S, et al. 5% imiquimod cream and reflectancemode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg. 2004;30(12 Pt 1):1462-9.10.1111/j.1524-4725.2004.30504.x15606733
    Search in Google Scholar
  35. 35. Weis SE. Current treatment options for management of anal intraepithelial neoplasia. Onco Targets Ther. 2013;10(6):651-65.10.2147/OTT.S38217368422023788834
    Search in Google Scholar
  36. 36. Beach DF, Somer R. Novel approach to Gorlin syndrome: a patient treated with oral capecitabine. J Clin Oncol. 2011;29(14):e397-401.10.1200/JCO.2010.33.339321357787
    Search in Google Scholar
  37. 37. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma. A systematic review. Arch Dermatol. 2009;145(12):1431-8.10.1001/archdermatol.2009.29120026854
    Search in Google Scholar
  38. 38. Thissen MR, Kuijpers DI, Krekels GA. Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases. J Drugs Dermatol. 2006;5(5):461-4.
    Search in Google Scholar
  39. 39. Doctoroff A, Oberlender SA, Purcell SM. Full-face carbon dioxide laser resurfacing in the management of a patient with the nevoid basal cell carcinoma syndrome. Dermatol Surg. 2003;29(12):1236-40.
    Search in Google Scholar
  40. 40. Alessi SS, Sanches JA, Oliveira WR, Messina MC, Pimentel ER, Festa Neto C. Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream. Clinics (Sao Paulo). 2009;64(10):961-6.10.1590/S1807-59322009001000005276307019841702
    Search in Google Scholar
  41. 41. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg. 2000;26(6):577-9.10.1046/j.1524-4725.2000.00003.x10848940
    Search in Google Scholar
  42. 42. Micali G, Lacarrubba F, Nasca MR, De Pasquale R. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin’s syndrome. Clin Exp Dermatol. 2003;28 (Suppl 1):19-23.10.1046/j.1365-2230.28.s1.7.x
    Search in Google Scholar
  43. 43. Micali G, De Pasquale R, Caltabiano R, Impallomeni R, Lacarrubba F. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report. J Dermatol Treat. 2002;13(3):123-7.10.1080/09546630260199488
    Search in Google Scholar
  44. 44. Vereecken P, Monsieur E, Petein M, Heenen M. Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome. J Dermatolog Treat. 2004;15(2):120-1.10.1080/09546630310017825
    Search in Google Scholar
  45. 45. Amon RB, Goodkin PE. Topical 5-fluorouracil and the basalcell- nevus syndrome. N Engl J Med. 1976;295(12):677-8.10.1056/NEJM197609162951217
    Search in Google Scholar
  46. 46. Strange PR, Lang PG Jr. Long-term management of basal cell nevus syndrome with topical tretinoin and 5-fluorouracil. J Am Acad Dermatol. 1992;27(5 Pt 2):842-5.10.1016/0190-9622(92)70262-E
    Search in Google Scholar
  47. 47. Van Ruth S, Jansman FG, Sanders CJ. Total body topical 5-fluorouracil for extensive non-melanoma skin cancer. Pharm World Sci. 2006;28(3):159-62.10.1007/s11096-006-9030-x
    Search in Google Scholar
  48. 48. Cristofolini M, Zumiani G, Scappini P, Piscioli F. Aromatic retinoid in the chemoprevention of the progression of nevoid basal-cell carcinoma syndrome. J Dermatol Surg Oncol. 1984;10(10):778-81.10.1111/j.1524-4725.1984.tb01181.x
    Search in Google Scholar
  49. 49. Goldberg LH, Hsu SH, Alcalay J. Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J Am Acad Dermatol. 1989;21(1):144-5.10.1016/S0190-9622(89)80359-7
    Search in Google Scholar
  50. 50. Lien MH, Sondak VK. Nonsurgical treatment options for basal cell carcinoma. J Skin Cancer. 2011; 2011: 571734.
    Search in Google Scholar
  51. 51. Shumack S, Rigel D. Treatment of non-melanoma skin cancer: immunotherapy. Acta Derm Venereol Suppl. 2003;214:18-22.
    Search in Google Scholar
  52. 52. Stockfleth E, Ulrich C, Hauschild A, Lischner S, Meyer T, Christophers E. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol. 2002;12(6):569-72.
    Search in Google Scholar
  53. 53. Tillman DK,. Carroll MT. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drugs Dermatol. 2008;7(Suppl 1):s7-14.
    Search in Google Scholar
  54. 54. Tillman DK Jr, Carroll MT. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience. Cutis. 2007;79(3):241-8.
    Search in Google Scholar
  55. 55. Wu JK, Oh C, Strutton G, Siller G. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol. 2006;47(1):46-8.10.1111/j.1440-0960.2006.00222.x16405483
    Search in Google Scholar
  56. 56. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehiclecontrolled studies.J Am Acad Dermatol. 2004;50(5):722-33.10.1016/j.jaad.2003.11.06615097956
    Search in Google Scholar
  57. 57. Slade HB, Owens ML, Tomai M, Miller RL. Imiquimod 5% cream (Aldara). Expert Opin Investig Drugs. 1998;7(3):437-49.10.1517/13543784.7.3.43715991984
    Search in Google Scholar
  58. 58. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114(1):135-41.10.1046/j.1523-1747.2000.00833.x10620129
    Search in Google Scholar
  59. 59. Cozzi SJ, Le TT, Ogbourne SM, James C, Suhrbier A. Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. Arch Dermatol Res. 2013;305(1):79-83.10.1007/s00403-012-1270-0353535622871992
    Search in Google Scholar
  60. 60. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30(30):3734-45. 10.1200/JCO.2012.41.868123008293
    Search in Google Scholar
DOI: https://doi.org/10.2478/sjdv-2014-0002 | Journal eISSN: 2406-0631
Journal RSS Feed
Language: English
Page range: 19 - 28
Published on: Jul 26, 2014
Published by: Serbian Association of Dermatovenereologists (SAD)
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Basal Cell Nevus Syndrome,
Carcinoma,
Basal Cell,
Neoplasms,
Multiple Primary,
Comorbidity,
Hodgkin Disease,
Diagnosis,
Aminoquinolines,
Treatment Outcome
Related subjects:
Medicine,
Clinical medicine,
Dermatological and veneral diseases

© 2014 Rumyana Yankova, Magdalina Gyurova, Donka Brambarova, published by Serbian Association of Dermatovenereologists (SAD)
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 6 (2014): Issue 1 (March 2014)Next article